KALYDECO
KALYDECO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in their CF gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is not for use in people with CF due to other mutations in the CF gene. KALYDECO is not effective in patients with CF with two copies of the F508del mutation (F508del/F508del) in the CF gene. It is not known if KALYDECO is safe and effective in children under 6 years of age.
KALYDECO
Industry:
Biotechnology Medical
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.kalydeco.com
Total Employee:
1+
Status:
Active
Contact:
877-752-5933
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network Font Awesome Apache Amazon
Official Site Inspections
http://www.kalydeco.com Semrush global rank: 1.98 M Semrush visits lastest month: 10.81 K
- Host name: a23-219-155-18.deploy.static.akamaitechnologies.com
- IP address: 23.219.155.18
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "KALYDECO"
KALYDECO - Crunchbase Company Profile & Funding
KALYDECO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following …See details»
KALYDECO® (ivacaftor) | Patient Information
Before taking KALYDECO, tell your doctor about all of your medical conditions, including if you: have liver or kidney problems; are allergic to KALYDECO or any ingredients in KALYDECO. See the Patient Information for a list of ingredients; …See details»
Kalydeco Company Profile | Management and Employees List
Kalydeco operates as a prescription medication that requires oversight from healthcare …See details»
Ivacaftor - Wikipedia
The U.S. Food and Drug Administration (FDA) approved ivacaftor in January 2012, Soon afterwards so too did the European Medicines Agency (EMA) and Canada and across some European countries. Lumacaftor/ivacaftor was approved by the FDA in July 2015, under breakthrough therapy status and under a priority review. See details»
Details for: KALYDECO - Drug and Health Products Portal
Product name: KALYDECO. Company name: VERTEX PHARMACEUTICALS (CANADA) …See details»
Health Canada Grants Marketing Authorization for KALYDECO
Mar 25, 2022 In Canada, Pr KALYDECO® is already approved for the treatment of people …See details»
Regulatory Decision Summary for Kalydeco - Drug and Health …
The purpose of this Supplement to a New Drug Submission (SNDS) for Kalydeco (ivacaftor) …See details»
Kalydeco - Overview, News & Similar companies | ZoomInfo.com
Nov 27, 2020 View Kalydeco (www.kalydeco.com) location in Massachusetts, United States , …See details»
Site Map | Kalydeco.com
What is KALYDECO ® (ivacaftor)?. KALYDECO is a prescription medicine used for the …See details»
Royalty Rights to Kalydeco, 2 CF Compounds Fetch $3.3B
Nov 19, 2014 Robert J. Beall, Ph.D., the foundation’s president and CEO, told the newspaper …See details»
Price Of CF Drug Kalydeco Could Drop In Canada And Australia …
Jun 2, 2014 Kalydeco was developed by Vertex Pharmaceuticals Inc. with significant …See details»
Health Canada Grants Marketing Authorization for KALYDECO
Aug 25, 2021 Pr KALYDECO® (ivacaftor) is now approved for additional eligible patients in …See details»
Regulatory Decision Summary for Kalydeco - Drug and Health …
This Supplement to a New Drug Submission (SNDS) for Kalydeco (ivacaftor) was filed to …See details»
Who is KALYDECO® (ivacaftor) For?
KALYDECO is a prescription medicine used for the treatment of cystic fibrosis (CF) in people …See details»
Vertex GPS™ Patient Support Program | KALYDECO® (ivacaftor)
Vertex GPS TM is here to help you get there. Vertex GPS TM is here to help you get there. …See details»
Kalydeco - CF Trust
Ivacaftor, known by its brand name Kalydeco, was the first precision medicine for cystic fibrosis …See details»
Regulatory Decision Summary for Kalydeco - Drug and Health …
The purpose of this priority Supplemental New Drug Submission (SNDS) is to seek regulatory …See details»
How KALYDECO® (ivacaftor) Works
KALYDECO is used in people age 1 month and older who have at least one mutation in their …See details»
Summary Basis of Decision for Kalydeco - Drug and Health …
Submission filed as a Level I – Supplement to expand the indication. The submission was …See details»
Regulatory Decision Summary for Kalydeco - Drug and Health …
Kalydeco (ivacaftor) is approved for the treatment of CF in patients 2 years and older with a …See details»